2012598-36-4
Chemical Structure
Finafloxacin-d4 hydrochloride
- CAS No.: 2012598-36-4
- Formula:C20H16D4ClFN4O4
- Molecular Weight:438.87
InChIKey: CQMSQUOHWYYEKM-DTXSOLBXSA-N
SMILES: O=C(C1=CN(C2C([2H])([2H])C2([2H])[2H])C3=C(C=C(F)C(N4C[C@]5([H])OCCN[C@@]5([H])C4)=C3C#N)C1=O)O.Cl
Biological Activity: Finafloxacin-d4 hydrochloride is the deuterated-labeled Finafloxacin hydrochloride (HY-13451A). Finafloxacin hydrochloride is an orally active fluoroquinolone antibacterial agent. Finafloxacin hydrochloride exerts broad-spectrum antibacterial activity by promoting DNA cleavage in the gyrase/topoisomerase IV (Topoisomerase IV) complex and inhibiting DNA synthesis. Finafloxacin hydrochloride is a weak substrate of NorA/Lde, can be effluxed by BpeAB-OprB/BpeEF-OprC, and can overcome BpeEF-OprC-mediated fluoroquinolone resistance, while also accumulating in macrophages and exhibiting intracellular bactericidal activity. Finafloxacin hydrochloride can be used for research on intracellular bacterial infections, melioidosis, tularemia, plague, acute otitis externa, complicated urinary tract infections, and pyelonephritis[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Finafloxacin-d4 hydrochloride | Finafloxacin-d4 hydrochloride is the deuterated-labeled Finafloxacin hydrochloride (HY-13451A). Finafloxacin hydrochloride is an orally active fluoroquinolone antibacterial agent. Finafloxacin hydrochloride exerts broad-spectrum antibacterial activity by promoting DNA cleavage in the gyrase/topoisomerase IV (Topoisomerase IV) complex and inhibiting DNA synthesis. Finafloxacin hydrochloride is a weak substrate of NorA/Lde, can be effluxed by BpeAB-OprB/BpeEF-OprC, and can overcome BpeEF-OprC-mediated fluoroquinolone resistance, while also accumulating in macrophages and exhibiting intracellular bactericidal activity. Finafloxacin hydrochloride can be used for research on intracellular bacterial infections, melioidosis, tularemia, plague, acute otitis externa, complicated urinary tract infections, and pyelonephritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Finafloxacin hydrochloride | Finafloxacin hydrochloride is an orally active fluoroquinolone antibacterial agent. Finafloxacin hydrochloride exerts broad-spectrum antibacterial activity by promoting DNA cleavage in the gyrase/topoisomerase IV (Topoisomerase IV) complex and inhibiting DNA synthesis. Finafloxacin hydrochloride is a weak substrate of NorA/Lde, can be effluxed by BpeAB-OprB/BpeEF-OprC, and can overcome BpeEF-OprC-mediated fluoroquinolone resistance, while also accumulating in macrophages and exhibiting intracellular bactericidal activity. Finafloxacin hydrochloride can be used for research on intracellular bacterial infections, melioidosis, tularemia, plague, acute otitis externa, complicated urinary tract infections, and pyelonephritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lemaire S, et al. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila[J]. International journal of antimicrobial agents, 2011, 38(1): 52-59.
- [2]. Randall L B, et al. Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance[J]. Journal of Antimicrobial Chemotherapy, 2017, 72(4): 1258-1260.
- [3]. Barnes KB, et al. Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection. Antimicrob Agents Chemother. 2021;65(6):e02294-20. Published 2021 May 18. [Content Brief]
- [4]. Daisuke Fukuda, et al. Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future, Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054. [Content Brief]
- [5]. Barnes K B, et al. Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to Burkholderia pseudomallei[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(7).
